Absci ABSI
NASDAQ ABSI
$8.97 +0.17 (+1.93%)
As of: Sep 4, 2026 · 11:51 AM EDT

Absci (ABSI) Income towards Parent Company (2020 - 2026)

Absci (ABSI) posted Income towards Parent Company of -$29.6 million for Q1 2026, little changed sequentially from -$29.6 million in Q4 2025, and down 12.35% YoY from -$33.8 million in Q1 2025.

Analysis

Absci (ABSI) Income towards Parent Company (2020 - 2026) Analysis & Trends

Absci has reported Income towards Parent Company for 7 years, with the latest figure at -$29.6 million in Q1 2026.

  • Quarterly Income towards Parent Company fell 12.35% year-over-year to -$29.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$118.4 million (down 10.2% YoY) and the FY2025 annual result came in at -$115.2 million, down 11.71% from the prior year.
  • Income towards Parent Company held at -$29.6 million in Q1 2026 per ABSI's latest filing, from -$29.6 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at -$19.5 million in Q4 2022 and troughed at -$41.7 million in Q2 2023.
  • A 5-year average of -$27.3 million and a median of -$27.4 million in 2024 frame the typical range for Income towards Parent Company.
  • The sharpest annual moves came in 2022 and 2024: Income towards Parent Company tumbled 169.62% in 2022, then jumped 40.61% in 2024.
  • Over 5 years, Income towards Parent Company stood at -$19.5 million in 2022, then retreated by 20.92% to -$23.5 million in 2023, then decreased by 23.1% to -$29.0 million in 2024, then decreased by 2.0% to -$29.6 million in 2025, then retreated by 0.13% to -$29.6 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered -$29.6 million, -$29.6 million, and -$28.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 140.21 Bn 132.36 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 86.04 Bn 78.05 Bn 3.93 Bn
3 Argenx Se 63.73 Bn 58.55 Bn 1.37 Bn
4 Moderna 57.59 Bn 52.46 Bn 52.00 Mn
5 Revolution Medicines 43.98 Bn 43.98 Bn -
6 BeOne Medicines 40.13 Bn 35.04 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.55 Bn 32.24 Bn 992.69 Mn
8 Royalty Pharma 28.60 Bn 27.77 Bn -
9 Insmed 27.70 Bn 26.54 Bn 358.27 Mn
10 Absci 1.41 Bn 1.21 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -33.21 Mn
Mar 31, 2026 -29.60 Mn
Dec 31, 2025 -29.56 Mn
Sep 30, 2025 -28.71 Mn
Jun 30, 2025 -30.57 Mn
Mar 31, 2025 -26.35 Mn
Dec 31, 2024 -28.98 Mn
Sep 30, 2024 -27.40 Mn
Jun 30, 2024 -24.75 Mn
Mar 31, 2024 -21.98 Mn
Dec 31, 2023 -23.55 Mn
Sep 30, 2023 -21.99 Mn
Jun 30, 2023 -41.67 Mn
Mar 31, 2023 -23.36 Mn
Dec 31, 2022 -19.47 Mn
Sep 30, 2022 -27.26 Mn
Jun 30, 2022 -28.68 Mn
Mar 31, 2022 -29.49 Mn
Dec 31, 2021 -25.17 Mn
Sep 30, 2021 -23.63 Mn